Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 389Observational 10Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1

Interventions

regorafenib 3Sunitinib 2Ramucirumab 2Oxaliplatin 2Fluorouracil 2zenocutuzumab 1zanidatamab 1ulixertinib 1trifluridine tipiracil drug combination 1sodium thiosulfate 1selpercatinib 1ripretinib 1peginterferon alfa-2a 1pegilodecakin 1onvansertib 1omburtamab I-131 1guselkumab 1futibatinib 1derazantinib 1balstilimab 1avapritinib 1Tenofovir 1Taxes 1Proton Pump Inhibitors 1Paclitaxel 1Melphalan 1Leucovorin 1Laparoscopy 1Imatinib Mesylate 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Paclitaxel × Gastrointestinal × Clear all
NCT02307812 2025-01-09

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Eli Lilly and Company

Approved for marketing
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡